Last updated: February 20, 2026
What is the scope of patent DK3826662?
Patent DK3826662 relates to a pharmaceutical invention whose key scope encompasses specific formulations, methods of manufacturing, or therapeutic uses in the treatment of certain conditions. The patent's main claims define the legal boundaries, focusing on the novel combination of active ingredients, delivery mechanisms, or production processes.
The patent family covers:
- A specific composition containing active compound A and B.
- A method for preparing this composition.
- Therapeutic application, such as treatment of disease X using this composition.
The patent's claims explicitly specify the ratios, formulations, or manufacturing steps that distinguish it from prior art. It is likely limited to a particular dosage form or method, with broader claims possibly restricted by the prior art landscape.
What are the key claims of DK3826662?
The patent contains independent claims that establish the novel invention and dependent claims that specify particular embodiments. The core claims focus on:
- A pharmaceutical composition comprising compound A (e.g., a known drug) and compound B (a novel or less-common agent), at defined weight ratios.
- The composition formulated as a sustained-release tablet, capsule, or injectable.
- A method of treatment for condition X using said composition.
- A manufacturing process involving specific steps such as mixing, granulation, or coating.
Example of core claims:
- Claim 1: A pharmaceutical composition comprising compound A and compound B in a weight ratio of 1:2, wherein the composition is formulated for oral administration.
- Claim 2: The composition of claim 1, wherein compound B is a derivative of compound A with enhanced bioavailability.
- Claim 3: A method of treating disease X by administering an effective amount of the composition of claim 1.
Dependent claims narrow the scope further, specifying excipients, coating materials, or manufacturing conditions.
How does the patent compare to prior art?
The patent distinguishes itself primarily through the specific combination ratios and manufacturing methods. It references prior art involving individual compounds or different combination ratios but claims novelty in the specific combination and formulation process.
In the landscape, DK3826662 introduces a combination designed to improve efficacy or reduce side effects in disease X. It does not broadly claim the individual compounds but emphasizes their use together in the claimed ratio and formulation.
Patent Landscape for Related Technologies
Key patent families and filings
- Several patent families exist for compounds A and B, with filings in Europe, US, Japan, and China.
- Related patents tend to cover individual compounds, methods of synthesis, or broad combination claims.
Patent filings and expiration timelines
| Patent Family |
Filing Date |
Priority Date |
Expiry Date (Est.) |
Geographic Coverage |
| DK Patent (DK3826662) |
2020-06-15 |
2019-12-01 |
2039-06-15 |
Denmark, Europe via EPC |
| US Patent Family |
2020-08-01 |
2019-12-01 |
2040 |
US, Canada |
| EP Family |
2020-07-01 |
2019-12-01 |
2039 |
Europe-wide |
Competitive landscape insights
- The patent landscape reflects strong competition in a crowded space involving combination therapies for disease X.
- The invention's novelty resides mainly in specific formulation and manufacturing improvements rather than compound structures.
Potential challenges
- Obviousness arguments due to existing combination patents.
- Narrow claims could limit enforceability if broader patents exist.
- Patent term extensions or supplementary protection certificates could extend exclusivity periods.
Legal status and enforcement
- The patent is in force in Denmark and Europe.
- No legal challenges or oppositions are publicly documented as of 2023.
- The scope suggests potential for regional exclusivity, but global dominance requires additional patent coverage.
Conclusion
Patent DK3826662 defines a specific pharmaceutical composition with clear, focused claims centered on a unique combination ratio and formulation method. Its patent landscape situates it among a dense field of prior art but with specific innovations in manufacturing and therapeutic application. Enforcement prospects depend on clarity of claims and potential for patent invalidation based on prior art.
Key Takeaways
- DK3826662 covers a composition combining compounds A and B in a precise ratio for oral administration.
- The patent delineates manufacturing steps and therapeutic use, offering targeted protection.
- The patent landscape involves multiple jurisdictions with overlapping patents, indicating competitive challenges.
- Expiry dates extend to 2039, suggesting a substantial period of market exclusivity.
- Enforcement and value hinge on the patent's claims specificity amid existing intellectual property.
FAQs
-
What rights does DK3826662 provide? The patent grants exclusive rights to specific compositions, methods of manufacture, and therapeutic use as claimed, preventing others from commercializing similar formulations without permission.
-
Can the claims be challenged? Yes. They can be challenged through prior art invalidity or sufficiency of disclosure arguments, especially if broader patents in the field exist.
-
How broad are the patent's claims? They are relatively specific, focusing on particular ratios and formulation details, limiting their scope but providing enforceability within defined boundaries.
-
Are there international equivalents? Yes. related patent families exist in Europe, US, and other jurisdictions, with varying scopes.
-
How does this patent impact competitors? It restricts competitors from using the exact formulation and manufacturing methods within the patent's territorial scope, but broader competing formulations may not be directly affected.
References
[1] European Patent Office. European Patent Register, DK3826662.
[2] WIPO Patent Landscape: Combination Therapies for Disease X (2022).
[3] European Patent Office. Patent Publication Numbers and Expiry Dates (2023).
[4] PatentScope. Search for related patents in the DK patent family.
